Figure 1.

Illustration of novel CD123 polyaptamer hydrogel edited by Cas9/sgRNA for AML targeted therapy and its action mechanism. (a) To construct CD123 polyaptamer hydrogel edited by Cas9/sgRNA, two types of RCA templates were designed. Both contained the CD123 aptamer SS30, but they differed in that one contained the sgRNA target sequence for Cas9/sgRNA-specific cleavage, while the other contained the complementary sgRNA target sequence. The two RCA products were crosslinked by sequence-specific hybridization between the sgRNA target and complementary sequences. (b) In the tumor microenvironment, the precise excision of the CD123 aptamer by Cas9/sgRNA can release a plenty of SS30 and further block the interaction between IL-3 and CD123, interfering activation of JAK2/STAT5 signaling pathway.